DB:6XB

Stock Analysis Report

Executive Summary

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Biophytis's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6XB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-20.6%

6XB

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

-85.1%

6XB

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: 6XB underperformed the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: 6XB underperformed the German Market which returned 6.1% over the past year.


Shareholder returns

6XBIndustryMarket
7 Day-20.6%-4.1%-5.7%
30 Day27.3%-8.2%-5.7%
90 Day-12.3%-2.0%-3.6%
1 Year-85.1%-85.1%4.0%3.7%9.3%6.1%
3 Yearn/a38.2%36.7%8.9%-0.7%
5 Yearn/a9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Biophytis's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biophytis undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Biophytis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Biophytis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Biophytis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biophytis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biophytis performed over the past 5 years?

-38.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6XB is currently unprofitable.

Growing Profit Margin: 6XB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6XB is unprofitable, and losses have increased over the past 5 years at a rate of -38.8% per year.

Accelerating Growth: Unable to compare 6XB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6XB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 6XB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Biophytis's financial position?


Financial Position Analysis

Short Term Liabilities: 6XB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 6XB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 6XB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 6XB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 6XB has a low level of unsold assets or inventory.

Debt Coverage by Assets: 6XB has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6XB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 6XB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -42.2% each year


Next Steps

Dividend

What is Biophytis's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 6XB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6XB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6XB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6XB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6XB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average board tenure


CEO

Stanislas Veillet (52yo)

€295,232

Compensation

Mr. Stanislas Veillet, Ph.D. serves as the Chairman of the Board and Chief Executive Officer of Biophytis SA. He has served as a Director at Drone Volt SA since May 4, 2018. Mr. Veillet served as Director  ...


CEO Compensation Analysis

Compensation vs Market: Stanislas's total compensation ($USD321.18K) is about average for companies of similar size in the German market ($USD415.76K).

Compensation vs Earnings: Stanislas's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Stanislas Veillet
Chairman of the Board & CEO0yrs€295.23k3.76% 349.7k
José-Alain Sahel
Member of Scientific Advisory Board0yrsno datano data
Thomas Voit
Member of Scientific Advisory Board2.3yrsno datano data
Dimitri Batsis
Independent Director2.1yrsno data0.000050% 4.7
Roger Fielding
Member of Scientific Advisory Board3.8yrsno datano data
Jean Franchi
Independent Director2.7yrsno datano data
René Lafont
Scientific Director & Member of Scientific Advisory Board0yrsno data0.17% 15.9k
Jean Mariani
Chairman of Scientific Advisory Board & Director3.8yrsno datano data
Nadine Coulm
Independent Director5.1yrsno data0.0032% 297.9
Ivana Kim
Member of Scientific Advisory Board3.8yrsno datano data

3.8yrs

Average Tenure

53yo

Average Age

Experienced Board: 6XB's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.8%.


Top Shareholders

Company Information

Biophytis SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biophytis SA
  • Ticker: 6XB
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €9.310m
  • Shares outstanding: 39.12m
  • Website: https://www.biophytis.com

Number of Employees


Location

  • Biophytis SA
  • Sorbonne Université
  • Bâtiment A 4 ème étage
  • Paris
  • Ile-de-France
  • 75252
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALBPSENXTPA (Euronext Paris)YesCommon StockFREURJul 2015
0D1WLSE (London Stock Exchange)YesCommon StockGBEURJul 2015
6XBDB (Deutsche Boerse AG)YesCommon StockDEEURJul 2015

Biography

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company’s lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Its second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry ager elated macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101). The company was founded in 2006 and is headquartered in Paris, France. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 23:50
End of Day Share Price2020/02/25 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.